RxDoctor Payments Data

Paul Grimm, MD

Pediatric Nephrology · Palo Alto, CANPI 1184705386

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $64,096 of the $98,511 with a category attached, or 65.1%. Amgen accounts for 88.5% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $28,656 and has fallen 82.9% since, to $4,893 in 2025. Among pediatric nephrology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$98,511in general payments, 2019–2025

Across 88 payments — averaging $1119.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$87K
  • Travere Therapeutics, Inc.$5K
  • Recordati_rare_diseases_inc.$3K
  • Genentech, Inc.$2K
  • AstraZeneca$625
  • Veloxis Pharmaceuticals, Inc.$121
  • plus $353 from 5 others
$18,007in research payments, 2019–2025

Across 7 payments — averaging $2572.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$18K

What the payments were for

  • Consulting fees$25,21326%
  • Speaking & faculty fees$64,09665%
  • Travel & lodging$6,3496%
  • Food & beverage$2,8543%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$98,511 in reported general payments places this provider in the 95th percentile of 75 pediatric nephrology providers in California.

See all pediatric nephrology providers in California

Medicare billing

Part B allowed, 2024
$17,959
Medicare patients
20
Services billed
188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProcysbiCysteamine Bitartrate22$1,983,536
CystadropsCysteamine Hcl12$108,168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProcysbi$87,134$1,983,53622 claims
Recordati_rare_diseases_inc.Cystadrops$3,422$108,16812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 75 pediatric nephrology providers in California.

Other pediatric nephrology in Palo Alto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →